Compare Biogen Inc (BIIB) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Biogen Inc trades at $208.25 (market cap $30.13B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.52. The key difference: Biogen Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | KOLD | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $49.39 |
52-Week Low | $128.93 | $13.58 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
KOLD, an inverse ETF tracking natural gas futures, trades at $28.34, down 1.05% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. Recent news highlights natural gas price volatility driven by weather forecasts and LNG export fluctuations, with the ETF positioned as a tactical tool for traders amid market swings.
The outlook for KOLD hinges on continued natural gas price volatility, offering short-term trading opportunities but carrying high risk due to its leveraged structure. Key risks include rapid price reversals in natural gas and macroeconomic shifts affecting energy demand, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
